Broomfield, CO —  November 21, 2011Colibri Heart Valve, LLC, a privately held medical device company, announced that Joseph B. Horn, Colibri’s president and chief executive officer, will present a corporate update at the 23rd annual Piper Jaffray Health Care Conference on Tuesday, November 29 at 8:10 a.m. Mr. Horn’s presentation will include an update on development of the investigational Colibri transcatheter heart valve (THV) system including the advantages Colibri’s system has over other systems currently available or in development.

The Piper Jaffray Health Care Conference is taking place in New York November 29‐30, 2011. The conference will feature presentations from executives from the industry’s leading public and private companies to an audience of nearly 1,500 attendees, including top institutional investors, equity portfolio managers and research analysts from the United States, Canada, the United Kingdom, Asia and Europe.

About Colibri Heart Valve, LLC

Colibri Heart Valve, LLC is a privately held medical device company committed to the research and development of novel heart valve technologies, including the Company’s dry, pre‐mounted, low‐profile, “package‐to‐patient” percutaneous Transcatheter Heart Valve (THV). The unique features of this system include its delivery technology and durable valve tissue, potentially providing major benefit by decreasing procedural vascular complications and improving overall TAVI outcomes. Colibri Heart Valve was founded by R. David Fish, MD, and David Paniagua, MD, pioneering interventional cardiologists.

Colibri’s corporate headquarters and pre‐commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas. For more information, visit: www.colibrihv.com.